| 試験進捗状況 | 試験終了/Completed |
| UMIN試験ID | UMIN000042907 |
| 受付番号 | R000048980 |
| 科学的試験名 | 試験食品摂取によるAGEs低減効果確認試験 |
| 一般公開日(本登録希望日) | 2022/01/07 |
| 最終更新日 | 2021/09/14 (2版) |
| 基本情報/Basic information | |||
| 一般向け試験名/Public title | 試験食品摂取によるAGEs低減効果確認試験 | Study on the AGEs-reducing effects induced by test food intakes | |
| 一般向け試験名略称/Acronym | 試験食品摂取によるAGEs低減効果確認試験 | Study on the AGEs-reducing effects induced by test food intakes | |
| 科学的試験名/Scientific Title | 試験食品摂取によるAGEs低減効果確認試験 | Study on the AGEs-reducing effects induced by test food intakes | |
| 科学的試験名略称/Scientific Title:Acronym | 試験食品摂取によるAGEs低減効果確認試験 | Study on the AGEs-reducing effects induced by test food intakes | |
| 試験実施地域/Region |
|
||
| 対象疾患/Condition | |||
| 対象疾患名/Condition | 健常成人男女 | Healthy male/female adults | |
| 疾患区分1/Classification by specialty |
|
||
| 疾患区分2/Classification by malignancy | 悪性腫瘍以外/Others | ||
| ゲノム情報の取扱い/Genomic information | いいえ/NO | ||
| 目的/Objectives | ||
| 目的1/Narrative objectives1 | 試験食品を12週間摂取することによるAGEs低減効果を確認する | To investigate AGEs-reducing effects associated with 12 weeks daily ingestion of the test food. |
| 目的2/Basic objectives2 | 安全性・有効性/Safety,Efficacy | |
| 目的2 -その他詳細/Basic objectives -Others | ||
| 試験の性質1/Trial characteristics_1 | 探索的/Exploratory | |
| 試験の性質2/Trial characteristics_2 | 実務的/Pragmatic | |
| 試験のフェーズ/Developmental phase | ||
| 評価/Assessment | ||
| 主要アウトカム評価項目/Primary outcomes | AGEs | Advanced glycation-end products |
| 副次アウトカム評価項目/Key secondary outcomes | 1. 空腹時血糖
2. HbA1c 3. 臨床検査値の変化 |
1. Blood sugar level on empty stomach
2. HbA1c 3. Changes in clinical test values |
| 基本事項/Base | ||
| 試験の種類/Study type | 介入/Interventional | |
| 試験デザイン/Study design | ||
| 基本デザイン/Basic design | 並行群間比較/Parallel | |
| ランダム化/Randomization | ランダム化/Randomized | |
| ランダム化の単位/Randomization unit | 個別/Individual | |
| ブラインド化/Blinding | 二重盲検/Double blind -all involved are blinded | |
| コントロール/Control | プラセボ・シャム対照/Placebo | |
| 層別化/Stratification | ||
| 動的割付/Dynamic allocation | ||
| 試験実施施設の考慮/Institution consideration | ||
| ブロック化/Blocking | ||
| 割付コードを知る方法/Concealment | 知る必要がない/No need to know | |
| 介入/Intervention | |||
| 群数/No. of arms | 3 | ||
| 介入の目的/Purpose of intervention | 予防・検診・検査/Prevention | ||
| 介入の種類/Type of intervention |
|
||
| 介入1/Interventions/Control_1 | 被験食品1を2回/日で12週間摂取。 | Ingestion of the test food 1 twice a day for 12 weeks. | |
| 介入2/Interventions/Control_2 | 被験食品2を2回/日で12週間摂取。 | Ingestion of the test food 2 twice a day for 12 weeks. | |
| 介入3/Interventions/Control_3 | 対照食品を2回/日で12週間摂取。 | Ingestion of the placebo food twice a day for 12 weeks. | |
| 介入4/Interventions/Control_4 | |||
| 介入5/Interventions/Control_5 | |||
| 介入6/Interventions/Control_6 | |||
| 介入7/Interventions/Control_7 | |||
| 介入8/Interventions/Control_8 | |||
| 介入9/Interventions/Control_9 | |||
| 介入10/Interventions/Control_10 | |||
| 適格性/Eligibility | |||||
| 年齢(下限)/Age-lower limit |
|
||||
| 年齢(上限)/Age-upper limit |
|
||||
| 性別/Gender | 男女両方/Male and Female | ||||
| 選択基準/Key inclusion criteria | (1) 同意取得時の年齢が20歳以上65歳未満の男女
(2) HbA1cが6.4%以下の者 (3) 1日2食、試験食品を摂取できる者 (4) 週に2回、試験食品を受け取れる者 (5) 当該試験について十分な説明を受け、内容を理解することができ、本人による文書同意が得られる者 |
(1) Males/females ranging in age from 20 to 64 at informed consent.
(2) Subjects equipped with no more than 6.4% of HbA1c. (3) Subjects who have no difficulty in ingesting the test food twice a day. (4) Subjects who have no difficulty in receiving the test food twice a week. (5) Subjects who can give informed consent to participate in this trial after being provided with an explanation of the protocol detail. |
|||
| 除外基準/Key exclusion criteria | (1) 薬剤治療中の者
(2) 糖質制限やダイエットを行っている者、また試験期間中にダイエットを予定している者(ダイエットの定義は運動による体重減少、食事の摂取量を減らすことによる体重減少) (3) 試験結果に影響を与える可能性のある特定保健用食品、機能性表示食品、サプリメント、健康食品を週3回以上摂取している者、また試験期間中に摂取制限が出来ない者 (4) 試験期間中に今までの生活習慣を変える予定がある者 (5) 食生活が極度に不規則な者 (6) 過去3ヶ月間に1日1食以下の日が週1回以上ある者 (7) アルコール多飲者 (8) 妊娠中または妊娠を予定している者、および授乳中の者 (9) 心臓、肝臓、腎臓、消化器等に重篤な疾患の既往歴および現病歴がある者 (10) 医薬品および食物にアレルギーがある者(主に小麦、卵、乳) (11) 他の医薬品または健康食品の臨床試験に参加中、試験終了後4週間以内、あるいは当該試験の参加同意後に他の臨床試験に参加する予定のある者 (12) 当該試験開始前月から成分献血あるいは全血200 mL献血を行った者 (13) 当該試験開始3ヶ月前から全血400 mL献血を行った男性 (14) 当該試験開始4ヶ月前から全血400 mL献血を行った女性 (15) 当該試験開始12ヶ月前からの採血量に、当該試験の予定総採血量を加えると1200 mLを超える男性 (16) 当該試験開始12ヶ月前からの採血量に、当該試験の予定総採血量を加えると800 mLを超える女性 (17) 試験責任医師または試験分担医師が本試験への参加が不適当と判断した者 |
(1) Subjects with some kind of continuous medical treatment.
(2) Subjects who are now under the restriction of carbohydrate with dieting (losing some weight by exercises and meal-controlling), and/or are planning to go on a diet, during this trial. (3) All through this trial, subjects who have any difficulty in refraining from taking steadily (not less than three times a week) in the health-specific/functional/supplementary/health foods, which might affect the test results. (4) Subjects who are planning to change their lifestyle. (5) Subjects with extremely irregular eating habits. (6) Subjects having not less than once a week , restricting their mealtimes to no more than once a day, within the last three months. (7) Subjects who extremely take alcohol. (8) Pregnant, possibly pregnant, or lactating women. (9) Subjects having present/previous medical history of serious diseases in heart, liver, kidney, and/or digestive organs. (10) Subjects with drug and/or food allergies, especially in wheat, eggs and milk. (11) Subjects who are now under the other clinical tests with some kind of medicine/food, or took part in those within four weeks before this trial, or are planning to participate in those after giving informed consent to take part in this trial. (12) Subjects who donated over 200 mL of their whole blood and/or blood components within a month before this trial. (13) Males who donated over 400 mL of their whole blood within the last three months before this trial. (14) Females who donated over 400 mL of their whole blood within the last four months before this trial. (15) Males who will be collected over 1200 mL of their blood within the last twelve months before this trial. (16) Females who will be collected over 800 mL of their blood within the last twelve months before this trial. (17) Others who have been determined as ineligible for participation, according to the principal/sub investigator's opinions. |
|||
| 目標参加者数/Target sample size | 21 | ||||
| 責任研究者/Research contact person | ||||||||||||||
| 責任研究者/Name of lead principal investigator |
|
|
||||||||||||
| 所属組織/Organization | CPCC株式会社 | CPCC Company Limited | ||||||||||||
| 所属部署/Division name | 臨床研究事業部 | Division of Clinical Research | ||||||||||||
| 郵便番号/Zip code | 101-0047 | |||||||||||||
| 住所/Address | 東京都千代田区内神田3-3-5 山和内神田ビル4F | 4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan | ||||||||||||
| 電話/TEL | 03-5297-3112 | |||||||||||||
| Email/Email | cpcc-contact@cpcc.co.jp | |||||||||||||
| 試験問い合わせ窓口/Public contact | ||||||||||||||
| 試験問い合わせ窓口担当者/Name of contact person |
|
|
||||||||||||
| 組織名/Organization | CPCC株式会社 | CPCC Company Limited | ||||||||||||
| 部署名/Division name | 臨床企画第一事業部 | Clinical Planning Department | ||||||||||||
| 郵便番号/Zip code | 101-0047 | |||||||||||||
| 住所/Address | 東京都千代田区内神田3-3-5 山和内神田ビル4F | 4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan | ||||||||||||
| 電話/TEL | 03-5297-3112 | |||||||||||||
| 試験のホームページURL/Homepage URL | ||||||||||||||
| Email/Email | cpcc-contact@cpcc.co.jp | |||||||||||||
| 実施責任組織/Sponsor | ||
| 機関名/Institute | その他 | CPCC Company Limited |
| 機関名/Institute (機関選択不可の場合) |
CPCC株式会社 | |
| 部署名/Department | ||
| 研究費提供組織/Funding Source | ||
| 機関名/Organization | その他 | Nisshin Seifun Group Inc. |
| 機関名/Organization (機関選択不可の場合) |
株式会社日清製粉グループ本社 | |
| 組織名/Division | ||
| 組織の区分/Category of Funding Organization | 営利企業/Profit organization | |
| 研究費拠出国/Nationality of Funding Organization | ||
| その他の関連組織/Other related organizations | ||
| 共同実施組織/Co-sponsor | ||
| その他の研究費提供組織/Name of secondary funder(s) | ||
| IRB等連絡先(公開)/IRB Contact (For public release) | ||
| 組織名/Organization | チヨダパラメディカルケアクリニック倫理審査委員会 | Institutional Review Board of Chiyoda Paramedical Care Clinic |
| 住所/Address | 〒101-0047 東京都千代田区内神田3-3-5山和内神田ビル2F | 2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan |
| 電話/Tel | 03-5297-5548 | |
| Email/Email | IRB@cpcc.co.jp | |
| 他機関から発行された試験ID/Secondary IDs | ||
| 他機関から発行された試験ID/Secondary IDs | いいえ/NO | |
| 試験ID1/Study ID_1 | ||
| ID発行機関1/Org. issuing International ID_1 | ||
| 試験ID2/Study ID_2 | ||
| ID発行機関2/Org. issuing International ID_2 | ||
| 治験届/IND to MHLW | ||
| 試験実施施設/Institutions | ||
| 試験実施施設名称/Institutions | ||
| その他の管理情報/Other administrative information | ||||||||
| 一般公開日(本登録希望日)/Date of disclosure of the study information |
|
|||||||
| 関連情報/Related information | ||
| プロトコル掲載URL/URL releasing protocol | ||
| 試験結果の公開状況/Publication of results | 未公表/Unpublished | |
| 結果/Result | ||
| 結果掲載URL/URL related to results and publications | ||
| 組み入れ参加者数/Number of participants that the trial has enrolled | ||
| 主な結果/Results | ||
| 主な結果入力日/Results date posted | ||
| 結果掲載遅延/Results Delayed | ||
| 結果遅延理由/Results Delay Reason | ||
| 最初の試験結果の出版日/Date of the first journal publication of results | ||
| 参加者背景/Baseline Characteristics | ||
| 参加者の流れ/Participant flow | ||
| 有害事象/Adverse events | ||
| 評価項目/Outcome measures | ||
| 個別症例データ共有計画/Plan to share IPD | ||
| 個別症例データ共有計画の詳細/IPD sharing Plan description | ||
| 試験進捗状況/Progress | ||||||||
| 試験進捗状況/Recruitment status | 試験終了/Completed | |||||||
| プロトコル確定日/Date of protocol fixation |
|
|||||||
| 倫理委員会による承認日/Date of IRB |
|
|||||||
| 登録・組入れ開始(予定)日/Anticipated trial start date |
|
|||||||
| フォロー終了(予定)日/Last follow-up date |
|
|||||||
| 入力終了(予定)日/Date of closure to data entry | ||||||||
| データ固定(予定)日/Date trial data considered complete | ||||||||
| 解析終了(予定)日/Date analysis concluded | ||||||||
| その他/Other | ||
| その他関連情報/Other related information | ||
| 管理情報/Management information | ||||||||
| 登録日時/Registered date |
|
|||||||
| 最終更新日/Last modified on |
|
|||||||
| 閲覧ページへのリンク/Link to view the page | |
| URL(日本語) | https://upload.umin.ac.jp/cgi-open-bin/ctr/ctr_view.cgi?recptno=R000048980 |
| URL(英語) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048980 |